Search results for "hepatitis"

showing 8 items of 1578 documents

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C

1997

Background/Aims: The role of interferon alfa treatment in improving morbidity endpoints in patients with chronic hepatitis C infection is currently under debate. The aim of this study was to evaluate the effectiveness of interferon in preventing hepatocellular carcinoma and decompensation in cirrhosis type C. Methods: A retrospective cohort study was carried out on 329 consecutive Caucasian patients with cirrhosis followed for a mean period of 5 years at seven tertiary care university hospitals. Inclusion criteria were biopsy-proven cirrhosis, anti-HCV positivity, abnormal serum aminotransferase levels and absence of complications of cirrhosis. Results: The yearly incidence of hepatocellula…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryIncidence (epidemiology)GastroenterologyAlpha interferonHepatitis Cmedicine.diseaseGastroenterologySurgeryLiver diseaseHepatocellular carcinomaInternal medicinemedicineDecompensationLiver functionbusinessInterferon alfamedicine.drug
researchProduct

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis : A longitudinal study of 1893 biopsy-proven no…

2021

[Background and Aim] Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We assessed the NASH distribution and its components across the fibrosis stages and their impact on the prognosis and their relationship with the concept of metabolic-associated fatty liver disease (MAFLD).

Liver Cirrhosismedicine.medical_specialtyCirrhosisSteatosisBiopsyGastroenterologydigestive systemBallooning03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFatty liver diseaseInternal medicineBiopsyNonalcoholic fatty liver diseasemedicineassociated fatty liver diseaseMetabolic-associated fatty liver diseaseHumansmetabolic&#8208Longitudinal StudiesFirst episodeInflammationHepatologymedicine.diagnostic_testballooning fatty liver disease inflammation metabolic-associated fatty liver disease natural coursesteatohepatitis steatosisbusiness.industryFatty liverNatural coursesteatohepatitismedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologySteatosisSteatohepatitisbusiness
researchProduct

Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells

1998

The aim of this study was to examine the possible immunomodulating effects of rhIL-12 on the immune response induced by different hepatitis C virus (HCV) antigens. Freshly isolated peripheral blood mononuclear cells (PBMC) of 33 patients with chronic HCV infection were stimulated with optimal concentrations of antigens from the NS3, NS4, NS5, and core region of HCV in the absence or presence of interleukin12 (IL-12). Stimulation by α-CD3 + α-CD28, lipopolysaccharide (LPS), and pokeweed mitogen (PWM) were used as controls. Proliferation and cytokine production were determined by 3H-thymidine uptake and enzyme-linked immunosorbent assay (ELISA) after 72 hr. After stimulation with antigen or a…

medicine.medical_treatmentHepatitis C virusPokeweed mitogenBiologymedicine.disease_causeVirologyPeripheral blood mononuclear cellInfectious DiseasesImmune systemCytokineAntigenVirologyImmunologyInterleukin 12medicineTumor necrosis factor alphaJournal of Medical Virology
researchProduct

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

2015

The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community, Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations…

0301 basic medicineriesgohumanosUltrafiltrationBacteremiaBlood DonorsHepacivirus030204 cardiovascular system & hematologyParasitemia/dk/atira/pure/subjectarea/asjc/2700/27200302 clinical medicineBlood plasmaScreening methodMedicinePathogenChromatographyultrafiltraciónfungemiaTransmission (medicine)Blood ScreeningbacteriemiaHematologyBlood Coagulation DisordersChromatography Ion ExchangeSettore MED/07 - Microbiologia e Microbiologia Clinicatransfusión de componentes sanguíneos/dk/atira/pure/subjectarea/asjc/2700/2730trastornos de la coagulación sanguíneaOncologyVIH-1RiskHepatitis B virusHaemophiliaBlood Component TransfusionHaemophiliaArticlepatógenos transmitidos por la sangre03 medical and health sciencesBlood-Borne PathogensHumansViremiacromatografíaBlood safety; Clotting; Haemophilia; Pathogen; TransfusionPathogenbusiness.industryDonor selectionTransfusionClottingdonantes de sangrevirus de la hepatitis Bmedicine.diseaseResidual risk030104 developmental biologyImmunologyHIV-1businessBlood safetyBlood Reviews
researchProduct

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

2017

AbstractNonalcoholic fatty liver disease (NAFLD) represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrhotic individuals. The rs641738 C > T MBOAT7/TMC4 variant predisposes to progressive NAFLD, but the impact on hepatic carcinogenesis is unknown. In Italian NAFLD patients, the rs641738 T allele was associated with NAFLD-HCC (OR 1.65, 1.08–2.55; n = 765), particularly in those without advanced fibrosis (p < 0.001). The risk T allele was linked to 3’-UTR variation in MBOAT7 and to reduced MBOAT7 expression in patients without severe fibrosis. The number of PNPLA3, TM6SF2, and MBOAT7 risk variants was associated with NAFLD-HCC independently of clinical fa…

0301 basic medicineLiver CirrhosisMaleAlcoholic liver diseasePathologyCirrhosisliver diseasesGastroenterology0302 clinical medicineSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasefatty liver-disease; cirrhosis; liver cancer; hepatitis C; hepatocellular carcinoma; liver diseases; fibrosis; carcinogenesis; fatty liver; allelesHCCProspective cohort studySettore MED/12 - GastroenterologiaMultidisciplinaryLiver NeoplasmsQRhepatocellular carcinomaSingle NucleotideMiddle Aged3. Good healthItalyfatty liver-diseaseHepatocellular carcinomaCohortMedicine030211 gastroenterology & hepatologyFemalecarcinogenesisAcyltransferases; Adult; Aged; Carcinoma Hepatocellular; Female; Gene Expression Regulation; Genotype; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Non-alcoholic Fatty Liver Disease; Polymorphism Single Nucleotide; Risk Factors; Alleles; Genetic Association Studies; Genetic Predisposition to Disease; Genetic VariationAdultmedicine.medical_specialtyCarcinoma HepatocellularGenotypeSciencePolymorphism Single NucleotideArticleliver cancer03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseAllelePolymorphismAllelesGenetic Association Studiesfatty liverAgedSettore MED/06 - ONCOLOGIA MEDICAbusiness.industrycirrhosisfibrosisCarcinomaGenetic VariationMembrane ProteinsHepatocellularmedicine.diseasedigestive system diseases030104 developmental biologyGene Expression Regulationhepatitis CbusinessAcyltransferasesTM6SF2Scientific Reports
researchProduct

July 2003: 62-year-old female with progressive muscular weakness

2004

The July 2003 Case of the Month (COM). A 62-year-old female patient experienced progressive muscular weakness over the last ten years, involving shoulder and pelvic girdle muscles, paraspinal and facial muscles. A biopsy was taken from the left deltoid muscle where hepatitis vaccination had taken place 4 weeks previously. The specimen revealed macrophagic myofasciitis due to the injection of aluminium-bound vaccines. The finding can be reproduced experimentally by injecting vaccines in rats. The pathomechanism is supposed to involve immune stimulation due to long term persistence of the adjuvant. Macrophagic myofasciitis has been suggested to occasionally cause myopathy but is supposed to b…

Viral Hepatitis Vaccinesmedicine.medical_specialtyAluminum HydroxideMass SpectrometryCases of the Month: July to September 2003Pathology and Forensic MedicineDiagnosis DifferentialBiopsymedicineHumansMuscle SkeletalMyopathyInclusion BodiesHepatitisMuscle WeaknessPelvic girdlemedicine.diagnostic_testbusiness.industryMacrophagesGeneral NeuroscienceMacrophagic myofasciitisMiddle Agedmedicine.diseaseMuscular Dystrophy FacioscapulohumeralSurgeryVaccinationMicroscopy ElectronFacial musclesmedicine.anatomical_structureFemaleNeurology (clinical)medicine.symptombusinessProgressive muscular weaknessBrain Pathology
researchProduct

Data from: The role of morbidly obesity in the promotion of metabolic disruptions and non-alcoholic steatohepatitis by Helicobacter Pylori

2017

Helicobacter pylori (HP) infection has been associated to an increased rate of type 2 diabetes (T2D) and liver disease through its effect on insulin resistance and systemic inflammation. However, results are inconstant and no studies exist in morbidly obese patients, in which both insulin resistance and inflammation coexist. Material and Methods: Cross-sectional study to evaluate the relationship between HP infection and alterations in carbohydrate metabolism, lipid profile, inflammation markers, and liver disease in patients awaiting for bariatric surgery. HP infection was histologically assessed in gastric antrum biopsy from 416 subjects. Liver biopsy was also available in 93 subjects. Re…

medicine and health careglucose abnormalitiesHelicobacter pyloriMedicineType 2 diabetesObesitynon-alcoholic steatohepatitisLife sciences
researchProduct

Imūnā atbildes reakcija uz vakcināciju pret vīrushepatītu B hemodialīzes pacientiem

2018

Pamatojums: Hemodialīzes (HD) pacientiem ir paaugstināts ar asinīm pārnesamām infekciju risks, piemēram, vīrushepatīta B infekcija (HBV). Pacientiem ar terminālu nieru mazspēju bieži ir imūnsistēmas nomākums, kas rezultējās ar nepietiekamu imūnās atbildes reakciju pret HBV vakcināciju. Adekvāta imunoloģiska atbilde it tad, ja anti-HBs-antivielu titrs >10 mSV/ml. Lai gan atbildes reakcija vispārējā populācijā ir aptuveni 95%, HD pacientiem tā ir robežās no 50-80%. Mērķis: noteikt HBV infekcijas izplatību, identificēt imūno atbildes reakciju HD pacientiem uz HBV vakcināciju un izvērtēt tās ietekmējošus klīniskus un laboratoriskus faktorus. Materiāli un metodes: Tika analizēta HBV izplatība HD…

hemodialysisviral hepatitis Bvaccinationimmune responseMedicīna
researchProduct